- Details
- Description
About Pirtobrutinib
Pirtobrutinib is an inhibits B cell lymphocyte proliferation and survival by binding and inhibiting Bruton's tyrosine kinase (BTK).
Mantle Cell Lymphoma
Indicated for relapsed or refractory mantle cell lymphoma (MCL) after at least 2 lines of systemic therapy, including a Bruton tyrosine kinase (BTK) inhibitor
200 mg PO qDay
Continue until disease progression or unacceptable toxicity
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Indicated for chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) in adults who have received at ≥2 prior lines of therapy, including a BTK inhibitor and a BCL-2 inhibitor
200 mg PO qDay
Continue until disease progression or unacceptable toxicity
Dosage Modifications
Asymptomatic lymphocytosis: Dose modification not recommended
Asymptomatic lipase increase: May not necessarily warrant a dose modification
Hematologic toxicities
- NOTE: Based on starting dose of 200 mg qDay
- Absolute neutrophil count (ANC) 0.5 to <1 x 109/L with fever and/or infection
- ANC <0.5 x 109/L lasting ≥7 days
- Platelet count 25 to <50 x 109/L with bleeding
- Platelet count <25 x 109/L
-
Modification
- First occurrence: Interrupt therapy until recovery to Grade 1 or baseline; restart at original dose (200 mg qDay)
- Second occurrence: Interrupt therapy until recovery to Grade 1 or baseline; restart at 100 mg qDay
- Third occurrence: Interrupt therapy until recovery to Grade 1 or baseline; restart at 50 mg qDay
- Fourth occurrence: Discontinue treatment
